Antidepressants augment natural killer cell activity: In vivo and in vitro

Neuropsychobiology

Volumn 39, Issue 1, 1999, Pages 18-24

  Frank, Matthew G ^a,b   Hendricks, Shelton E ^a,c   Johnson, Donald R ^a,b   Wieseler, Julie L ^c   Burke, William J ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF NEBRASKA AT OMAHA   (United States)

Author keywords

Antidepressants; Depression; Fluoxetine; Natural killer cell activity

Indexed keywords

ANTIDEPRESSANT AGENT; FLUOXETINE; NORFLUOXETINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; ASSAY; CLINICAL ARTICLE; DEPRESSION; DISEASE SEVERITY; DRUG BLOOD LEVEL; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; LYMPHOID CELL; MALE; MONONUCLEAR CELL; NATURAL KILLER CELL; PRIORITY JOURNAL;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DEPRESSION; FEMALE; FLUOXETINE; HUMANS; IMMUNOASSAY; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; PAROXETINE; PSYCHIATRIC STATUS RATING SCALES; STIMULATION, CHEMICAL;

EID: 0032957368     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000026555     Document Type: Article

References (36)

1. Stein M, Miller AH, Trestman RL: Depression, the immune system, and health and illness. Arch Gen Psychiatry 1991;48:171-177.
2. Zorrilla EP, McKay JR, Luborsky L, Schmidt K: Relation of stressors and depressive symptoms to clinical progression of viral illness. Am J Psychiatry 1996;153:626-635.
3. Glassman AH, Shapiro PA: Depression and the course of coronary artery disease. Am J Psychiatry 1998;155:4-11.
4. Urch A, Muller Ch, Aschauer H, Resch F, Zielinski CC: Lytic effector cell function in schizophrenia and depression. J Neuroimmunol 1988;18:291-301.
5. Nerozzi D, Santoni A, Bersani G, Magnani A, Bressan A, Pasini A, Antonozzi I, Frajese G: Reduced natural killer cell activity in major depression: neuroendocrine implications. Psychoneuroendocrinology 1989;14:295-301.
6. Irwin M; Smith TL, Gillin JC: Low natural killer cytotoxicity in major depression. Life Sci 1987;41:2127-2133.
7. Kronfol Z, Nair M, Goodson J, Goel K, Haskett R, Schwartz S: Natural killer cell activity in depressive illness: Preliminary report. Biol Psychiatry 1989;26:753-756.
8. Irwin M, Patterson T, Smith TL, Caldwell C, Brown SA, Gillin JC, Grant I: Reduction of immune function in life stress and depression. Biol Psychiatry 1990;27:22-30.
9. Irwin M, Brown M, Patterson T, Hauger R, Mascovich A, Grant I: Neuropeptide Y and natural killer cell activity: Findings in depression and Alzheimer caregiver stress. FASEB J 1991;5:3100-3107.
10. Caldwell CL, Irwin M, Lohr J: Reduced natural killer cell cytotoxicity in depression but not in schizophrenia. Biol Psychiatry 1991;30:1131-1138.
11. Kronfol Z, Starkman M, Nair M: Natural killer cell activity in major depression and Cushing's syndrome. Biol Psychiatry 1991;29:43A-185A.
12. Irwin M, Lacher U, Caldwell C: Depression and reduced natural killer cytotoxicity: A longitudinal study of depressed patients and control subjects. Psychol Med 1992;22:1045-1050.
13. Maes M, Stevens W, Peeters D, DeClerck L, Scharpe S, Bridts C, Schotte C, Cosyns P: A study on the blunted natural killer cell activity in severely depressed patients. Life Sci 1992; 50:505-513.
14. Evans DL, Folds JD, Petitto JM, Golden RN, Pedersen CA, Corrigan M, Gilmore JH, Silva SG, Quade D, Ozer H: Circulating natural killer cell phenotypes in men and women with major depression. Arch Gen Psychiatry 1992; 49:388-395.
15. Zisook S, Shuchter SR, Irwin M, Darko DF, Sledge P, Resovsky K: Bereavement, depression, and immune function. Psychiatry Res 1994;52:1-10.
16. Kook AI, Mizruchin A, Odnopozov N, Gershon H, Segev Y: Depression and immunity: the biochemical interrelationship between the central nervous system and immune system. Biol Psychiatry 1995;37:817-819.
17. Herberman RB, Djeu JY, Kay HD, Ortaldo JR, Riccardi C, Bonnard GD, Holden HT, Fagnani R, Santoni A, Puccetti P: Natural killer cells: Characteristics and regulation of activity. Immunol Rev 1979;44:43-70.
18. Herberman RB, Ortaldo JR: Natural killer cells: Their role in defenses against disease. Science 1981;214:24-30.
19. Levy EM, Borrelli DJ, Mirin SM, Salt P, Knapp PH, Pierce C, Fox BH, Black PH: Biological measures and cellular immunological function in depressed psychiatric inpatients. Psychiatry Res 1991;36:157-167.
20. Miller AH, Asnis GM, Lackner C, Halbreich U, Norin AJ: Depression, natural killer cell activity, and cortisol secretion. Biol Psychiatry 1991;29:878-886.
21. Schliefer SJ, Keller SE, Bond RN, Cohen J, Stein M: Major depressive disorder and immunity. Arch Gen Psychiatry 1989;46:81-87.
22. Levy SM, Herberman RB, Simons A, Whiteside T, Lee J, McDonald R, Beadle M: Persistenly low natural killer cell activity in normal adults: immunological, hormonal and mood correlates. Nat Immun Cell Growth Regul 1989;8:173-186.
23. Pariante CM, Miller AH: Natural killer cell activity in major depression: A prospective study of the in vivo effects of desmethylimipramine treatment. Eur Neuropsychopharmacol 1995;suppl:83-88.
24. Hickie I, Silove D, Hickie C, Wakefield D, Lloyd A: Is there immune dysfunction in depressive disorders? Psychol Med 1990;20:755-761.
25. Gold PW, Goodwin FK, Chrousos GP: Clinical and biochemical manifestations of depression. N Engl J Med 1988;319:348-420.
26. Barden N, Reul JM, Holsboer F: Do antidepressants stabilize mood through actions on the hypothalamic-pituitary-adrenocortical system? Trends Neurosci 1994;18:11.
27. Balogh S, Fitzpatrick DF, Hendricks SE, Paige SR: Increases in heart rate variability with successful treatment in patients with major depressive disorder. Psychopharmacol Bull 1993; 8:201-206.
28. Faraj BA, Olkowski ZL, Jackson RT: Expression of a high-affinity serotonin transporter in human lymphocytes. Int J Immunopharmacol 1994;16:561-567.
29. Hellstrand K, Hermodsson S: Enhancement of human natural killer cell cytotoxicity by serotonin: Role of non-T/CD16+ NK cells, accessory monocytes, and 5-HT1a receptors. Cell Immunol 1990;127:199-214.
30. Spitzer RL, Williams JB, Gibbon M, First MB: Structured clinical interview for DSM-III-R-Non-Patient Edition (SCID-NP, Version 1.0). Washington, American Psychiatric Press, 1990.
31. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
32. Pross HF, Baines MG, Rubin P, Shragge P, Patterson MS: Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX. The quantitation of natural killer cell activity. J Clin Immunol 1981;1:51-63.
33. Wong SH, Dellafera SS, Fernandes R: Determination of fluoxetine and norfluoxetine by high-performance liquid chromatography. J Chromatogr 1990;499:601-608.
34. Burke WJ, Hendricks SE, McArthur-Campbell D, Jacques D, Stull T: Fluoxetine and norfluoxetine concentrations and clinical response to weekly versus daily dosing. Psychopharmacol Bull 1996;32:27-32.
35. Shekelle RB, Raynor WJ, Ostfeld AM, Garron DC, Bieliauskas LA, Liu SC, Maliza C, Oglesby P: Psychological depression and 17-year risk of death from cancer. Psychosom Med 1981;43: 117-125.
36. Cohen S, Herbert TB: Health psychology: Psychological factors and physical disease from the perspective of human psychoneuroimmunology. Annu Rev Psychol 1996;47:113-142.